Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2016—Chembio Diagnostics will begin selling its Sure Check HIV 1/2 Assay in the U.S. market on June 1. The product is currently distributed in the United States by Alere under Alere’s Clearview Complete brand, and Chembio has notified Alere that it will not renew or extend the distribution agreement when it terminates on May 31.
March 2016—SciGene introduced a high-capacity system for performing FISH hybridization assays. The system consists of one CytoBrite Slide Incubation System for performing rapid probe denaturation on batches of 12 FISH slides and one CytoBrite Slide Oven for overnight hybridizations of 60 slides. Removable slide trays streamline slide setup and transfers between instruments.
March 2016—Sakura Finetek USA announced the acquisition of Genemed Biotechnologies’ tissue-based advanced staining business for cancer detection, diagnosis, and monitoring. Genemed’s liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business.
March 2016—ScyTek Laboratories announced the availability of its Multiplex TTF-1 and Cytokeratin 5 Cocktail. This multiplex cocktail of TTF-1 and cytokeratin 5 produces two-color, high-contrast staining for differentiating primary adenocarcinoma of the lung from metastatic carcinomas of the breast and malignant mesothelioma. This cocktail can increase sensitivity and diagnostic utility in differential diagnosis of the tumor.
March 2016—PerkinElmer has acquired Vanadis Diagnostics. Based in Sweden, Vanadis is developing a novel solution for non-invasive prenatal testing based on digital analysis of cell-free DNA.
March 2016—Definiens released its Tissue Studio 4.2 software package. The updated product suites provide improved image analysis functionality for scientists in academic medical centers, comprehensive cancer centers, and biotech and pharmaceutical companies.
March 2016—Quidel has received the CE mark for its Sofia S. pneumoniae fluorescent immunoassay for use with the Sofia Fluorescent Immunoassay Analyzer. The Sofia S. pneumoniae FIA enables the qualitative detection of Streptococcus pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid of patients with meningitis in 10 minutes.
March 2016—Medivation and NanoString Technologies have entered into a collaboration, together with Astellas Pharma, to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString’s nCounter Dx Analysis System.
March 2016—Quantimetrix introduced a new formulation for Dip&Spin Urinalysis Dipstick/Microscopics Control. The formulation now features improved crystal sediment components with calcium oxalate dihydrate in their native octahedral morphology and are readily identifiable via standard light microscopy and automated microscopy methods.
March 2016—Advanced Biological Laboratories launched its DeepChek SingleRound HIV and Hepatitis C Virus Genotyping and Sequencing assays. The DeepChek SingleRound HIV RT-PCR and Sequencing Assay detects the major HIV-1 subtypes and combines the reagents (including enzymes) and protocols required to perform the amplification and sequencing of reverse transcriptase, protease, and integrase.
